The Sirtex Medical Limited (ASX: SRX) share price has dropped more than 5% today to trade around $34.30, despite the health care company declaring a record interim profit.

Sirtex is primarily known for manufacturing and distributing Sir-Spheres, a radioactive product designed to combat liver cancer. In the six months to December 2015, global dose sales increased 15.7% to 5,728 units, resulting in revenues of $112.6 million.

Across the board, this was a stellar result by any definition.

Revenues up 4%, net profit up 46.9% to $25.9 million, earnings per share up 45% to 45.4 cents and the company keeps spitting out cash – with the cash balance surging 33% to $73.7 million. Margins are also growing at a rate of knots, with net profit margin up to 23% from 21.9% in the last year.

Perhaps the only real disappointment was operating cash flow, which increased only marginally compared to the first half of the 2015 financial year.

Income-seeking investors hoping for a dividend were also likely disappointed no dividend was announced – but that is consistent with previous years. More than likely, Sirtex will pay a single dividend when it reports in August this year – like it did last year.

CEO Gilman Wong said in the announcement, “I am pleased with our record first half profit result, which reflects the significant progress we have made in continuing to grow the business. The first half result is consistent with our dose sales objectives for the full financial year.”

So what?

It seems the market wanted more or higher growth, given Sirtex is trading on a trailing P/E ratio of 48x, and previous historical growth in dose sales and earnings.

However, ignoring the market reaction for now and focusing on the results alone suggests this was a strong first half result.

What now for Sirtex?

The company appears well set to report solid growth for the full 2016 financial year – and beyond. Sirtex says it expects the full year growth rate of dose sales to be at least in line with its compound annual growth rate over five years at 19.7% [emphasis mine].

Sirtex also has a number of trials and clinical programs underway, with the primary goal of proving that Sir-Spheres can be used as a front-line weapon against liver cancer, rather than at a later stage.

The current share price dip may be an opportunity for long-term focused investors.

Discover the 'new breed' of blue chips that could take your portfolio higher in 2016

Forget BHP and Woolworths. These 3 "new breed" top blue chips for 2016 pay fully franked dividends and offer the very real prospect of significant capital appreciation. Click here to learn more.

The report is free! No credit card required.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool writer/analyst Mike King owns shares in Sirtex. You can follow Mike on Twitter @TMFKinga

Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.